MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Immunocore Holdings PLC ADR

Chiusa

33.85 -0.67

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

33.77

Massimo

34.94

Metriche Chiave

By Trading Economics

Entrata

-15M

-10M

Vendite

4.1M

98M

Margine di Profitto

-10.514

Dipendenti

493

EBITDA

-11M

-15M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+73.8% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

80M

1.7B

Apertura precedente

34.52

Chiusura precedente

33.85

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 ott 2025, 20:45 UTC

Utili

Costco Wholesale Sales Climb in September, Early October

8 ott 2025, 20:12 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 ott 2025, 16:39 UTC

I principali Market Mover

Mining Shares Rise as Gold Prices Soar

8 ott 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen -- Market Talk

8 ott 2025, 23:43 UTC

Discorsi di Mercato

Gold Falls on Possible Profit-Taking -- Market Talk

8 ott 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics to Finance Acquisition Using Internal Funds

8 ott 2025, 23:17 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 ott 2025, 23:16 UTC

Acquisizioni, Fusioni, Takeovers

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 ott 2025, 21:54 UTC

Discorsi di Mercato
Utili

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 ott 2025, 21:30 UTC

Discorsi di Mercato

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 ott 2025, 21:26 UTC

Discorsi di Mercato
Utili

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 ott 2025, 19:15 UTC

Discorsi di Mercato

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 ott 2025, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 ott 2025, 18:47 UTC

Discorsi di Mercato

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs Will Remain a Publicly Traded Co >TASK

8 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 ott 2025, 18:07 UTC

Discorsi di Mercato

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 ott 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

8 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 ott 2025, 15:57 UTC

Discorsi di Mercato

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 ott 2025, 15:56 UTC

Discorsi di Mercato

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 ott 2025, 15:53 UTC

Discorsi di Mercato

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 ott 2025, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 ott 2025, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 ott 2025, 15:43 UTC

Acquisizioni, Fusioni, Takeovers

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 ott 2025, 15:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

73.8% in crescita

Previsioni per 12 mesi

Media 59.11 USD  73.8%

Alto 100 USD

Basso 34 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

7

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

27.895 / 30.16Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat